Press release
Necrotizing Enterocolitis Pipeline: Breakthrough Therapeutics Advancing in Neonatal Care | DelveInsight
Necrotizing Enterocolitis Pipeline
DelveInsight's "Necrotizing Enterocolitis - Pipeline Insight, 2025" tracks the progress of these emerging therapies, offering a granular view of the clinical pipeline, from early development to regulatory milestones. The report emphasizes key drug targets, trial outcomes, and development hurdles specific to this vulnerable population.
This pipeline report delivers a holistic 360° view of NEC drug development, highlighting the most promising candidates by development phase, route of administration, molecule type, and MOA. It also explores commercial potential, strategic partnerships, and growth forecasts aimed at improving neonatal outcomes and reducing NEC-associated mortality.
Key Takeaways from the Necrotizing Enterocolitis Pipeline Report
• DelveInsight's necrotizing enterocolitis pipeline analysis depicts a strong space with 2+ active players working to develop 2+ pipeline drugs for necrotizing enterocolitis treatment.
• The leading necrotizing enterocolitis companies include Infant Bacterial Therapeutics, Noveome Biotherapeutics, Siolta Therapeutics, and others are evaluating their lead assets to improve the necrotizing enterocolitis treatment landscape.
• Key necrotizing enterocolitis pipeline therapies in various stages of development include IBP-9414, ST266, STMC-106, and others.
• In May 2025, The NEC baby formula multidistrict litigation (MDL) added 27 new cases in April, bringing the total to approximately 710 pending cases in federal court, with additional cases in state courts, reflecting ongoing legal challenges for formula manufacturers.
• In May 2025, a U.S. federal judge allowed expert testimony asserting that preterm baby formulas produced by Abbott Laboratories and Mead Johnson can cause NEC, a significant decision as the companies face over 700 federal lawsuits.
• In February 2025, Dr. Venkatesh Sampath received a $2.5 million NIH grant to investigate the mechanisms underlying NEC in premature infants, aiming to enhance understanding and develop preventive strategies.
• In October 2024, The FDA, CDC, and NIH hosted a public workshop titled "Live Biotherapeutic Products to Prevent Necrotizing Enterocolitis in Very Low Birth Weight Infants," focusing on regulatory and scientific issues related to live biotherapeutic products for NEC prevention.
• In September 2024, the NIH released a report recommending 17 strategies to advance research on NEC, emphasizing the need for a better understanding of disease mechanisms, early diagnosis, and the development of preventive and therapeutic interventions.
• In February 2024, researchers at Lurie Children's Hospital reported that recombinant human insulin-like growth factor 1 and its binding protein-3 (rhIGF-1/BP3) protected neonatal mice from NEC, paving the way for clinical trials targeting NEC prevention in preterm infants.
Request a sample and discover the recent breakthroughs happening in the necrotizing enterocolitis pipeline landscape @ https://www.delveinsight.com/report-store/necrotizing-enterocolitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Necrotizing Enterocolitis Overview
Necrotizing enterocolitis (NEC) is a serious gastrointestinal condition primarily affecting premature and low birth weight infants. It involves inflammation and bacterial invasion of the intestinal wall, leading to tissue damage, necrosis, and potentially life-threatening complications like intestinal perforation, peritonitis, sepsis, and death-with mortality rates reaching up to 50%. Symptoms are often nonspecific, including poor feeding, vomiting, lethargy, and abdominal tenderness, requiring early recognition and intervention for better outcomes.
The exact cause of NEC is not fully understood, but it is linked to a combination of factors such as prematurity, immature gut function, impaired blood flow, and a weakened immune response. Bacterial invasion and inflammation play key roles in disease progression. Formula feeding has been associated with higher NEC risk, possibly due to its impact on gut microbiota. Other contributing factors may include genetic predisposition and hypoxic events, particularly in infants with congenital heart conditions.
Find out more about necrotizing enterocolitis medication @ https://www.delveinsight.com/report-store/necrotizing-enterocolitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Necrotizing Enterocolitis Treatment Analysis: Drug Profile
IBP-9414 - Infant Bacterial Therapeutics
IBP-9414 is a novel biological therapy developed to prevent necrotizing enterocolitis (NEC) in premature infants. It contains Lactobacillus reuteri, a beneficial bacterial strain naturally found in breast milk, known for its anti-inflammatory and gut-protective properties. The live bacterium supports gut motility, mucosal maturation, and reduces pathogenic activity-all critical factors in NEC prevention. In addition to reducing NEC risk, IBP-9414 aims to improve feeding, growth, and overall health in vulnerable neonates. The therapy is currently in Phase III development for NEC.
ST266 - Noveome Biotherapeutics
ST266 is an investigational, cell-free biologic therapy being developed by Noveome Biotherapeutics for the treatment of NEC. Derived from amnion-based cells, ST266 contains hundreds of bioactive proteins that work to reduce intestinal inflammation, inhibit TLR4 signaling, and support gut repair. Preclinical data have shown promising protective effects against NEC. The therapy has received Orphan Drug Designation and is currently in Phase I/II clinical trials.
Learn more about the novel and emerging necrotizing enterocolitis pipeline therapies @ https://www.delveinsight.com/report-store/necrotizing-enterocolitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Necrotizing Enterocolitis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule
Scope of the Necrotizing Enterocolitis Pipeline Report
• Coverage: Global
• Key Necrotizing Enterocolitis Companies: Infant Bacterial Therapeutics, Noveome Biotherapeutics, Siolta Therapeutics, and others.
• Key Necrotizing Enterocolitis Pipeline Therapies: IBP-9414, ST266, STMC-106, and others.
Dive deep into rich insights for drugs used for necrotizing enterocolitis treatment; visit @ https://www.delveinsight.com/report-store/necrotizing-enterocolitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Necrotizing Enterocolitis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Necrotizing Enterocolitis Pipeline Therapeutics
6. Necrotizing Enterocolitis Pipeline: Late-Stage Products (Phase III)
7. Necrotizing Enterocolitis Pipeline: Mid-Stage Products (Phase II)
8. Necrotizing Enterocolitis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Necrotizing Enterocolitis Pipeline: Breakthrough Therapeutics Advancing in Neonatal Care | DelveInsight here
News-ID: 4001905 • Views: …
More Releases from DelveInsight
Nanomedicine Market to Register a CAGR of 11.39% by 2032, Driven by Expanding Ap …
The nanomedicine market is experiencing rapid growth, propelled by the increasing adoption of nanotechnology in drug delivery, diagnostics, regenerative medicine, and theranostics. Rising demand for personalized and precision medicine, coupled with advancements in nanoparticle engineering, is enhancing therapeutic efficacy while minimizing side effects. Key innovations such as liposomal formulations, polymeric nanoparticles, and nanocarriers for oncology, cardiovascular, and neurological disorders are significantly transforming treatment paradigms. Additionally, the integration of nanomedicine in…
Cardiac Rhythm Management Devices Market to See Robust Growth Through 2032, Fuel …
The cardiac rhythm management (CRM) devices market is poised for steady expansion through 2032, driven by rising prevalence of atrial fibrillation and heart failure, an aging population, and broader adoption of minimally invasive and digitally connected cardiac care. Advancements in leadless pacemakers, subcutaneous ICDs, cardiac resynchronization therapy (CRT), and pulsed-field ablation (PFA) are improving procedural safety, battery longevity, and patient quality of life. Seamless remote monitoring, AI-enabled arrhythmia detection, and…
Embolic Protection Devices Market to Grow at a CAGR of 7.58% by 2032, Driven by …
The embolic protection devices market is expected to register steady growth through 2032, propelled by the increasing incidence of cardiovascular diseases, rising adoption of minimally invasive transcatheter procedures, and growing awareness of stroke prevention during interventions. Advancements in filter-based, balloon-based, and proximal occlusion devices are improving procedural safety and patient outcomes, while expanding indications in peripheral and neurovascular procedures are further broadening the market scope. Favorable reimbursement policies and an…
Ablation Devices Market to Register a CAGR of 11.65% by 2032, Fueled by Growing …
The ablation devices market is projected to witness robust growth through 2032, driven by the rising prevalence of cancer, cardiovascular disorders, and chronic pain, along with increasing demand for minimally invasive procedures. Technological advancements, such as next-generation radiofrequency, microwave, cryoablation, and laser-based systems, are enhancing precision, safety, and treatment outcomes. Additionally, expanding applications in dermatology, aesthetics, and gynecology, coupled with favorable reimbursement policies and growing awareness among clinicians, are expected…
More Releases for Necrotizing
Necrotizing Enterocolitis Drugs Market Forecast 2023-2030
Advancements in Necrotizing Enterocolitis Market Attract Significant Research and Investment:
The necrotizing enterocolitis (NEC) market is experiencing a surge in research activities and technological advancements, driven by the launch of new antibiotics and antifungals for NEC treatment. Noteworthy players like Noveome Biotherapeutics, Inc., Pfizer Inc., Endo Pharmaceuticals Inc., and Sanofi are actively contributing to the market's growth.
The rising availability of approved antibiotics, increased cases of NEC, and intensified research and development…
Necrotizing Fasciitis (NF) Treatment Market | Abbott, Atox Bio, Bristol-Myers Sq …
The global necrotizing fasciitis (nf) treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the necrotizing fasciitis (nf) treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving…
Global Necrotizing Autoimmune Myositis Market - Opportunities & Forecasts, 2020- …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global necrotizing autoimmune myositis market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able…
Necrotizing Fasciitis Treatment
Necrotizing Fasciitis Treatment Market describes its growth, size, share, Forecast and trends to 2025
Necrotizing Fasciitis Treatment Market Production and Demand Analysis 2019 to 2025
Necrotizing Fasciitis Treatment Market 2019 Manufacturing Analysis and Development Forecast 2025
Necrotizing Fasciitis Treatment Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025
Necrotizing Fasciitis Treatment Market to Insight By 2025: Top Key Vendors
Necrotizing fasciitis NF, commonly known as flesh-eating disease, is an infection that results in…
Global Necrotizing Skin infections Treatment Market Size, Status and Forecast 20 …
Market Research Report Store offers a latest published report on Necrotizing Skin infections Treatment Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Necrotizing Skin infections Treatment players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Necrotizing Skin…
Necrotizing Skin infections Treatment Market Forecast and Segments, 2018-2028
Necrotizing skin infections ranks among the most rarely found diseases but are highly lethal infection. Necrotizing skin infection arise primarily in any layer of skin soft tissue such as dermis and epidermis that are associated with necrotizing changes. Necrotizing skin infection is also commonly called as “Flesh eating disease”. Necrotizing skin infections penetrates deeper layers of soft tissues and rapidly spreads along facial planes.
This infection majorly infects the adipose tissue…
